United StatesThe Michigan Supreme Court has allowed the state's attorney general to investigate Eli Lilly over its insulin pricing practices. In a 4-to-3 decision, the court overturned a lower court ruling that had blocked the investigation, which began four years ago. The attorney general, Dana Nesel, argued that Lilly's pricing strategies violated state consumer protection laws by significantly increasing insulin costs. The state alleges that these high prices forced some patients to ration or avoid insulin, leading to severe health consequences including disability and death. The case centers on three Lilly insulin products, Lispro, Humalog, and Basaglar, and highlights concerns about pharmaceutical pricing impacting patient care.
Bias read (Center): The article presents the legal proceedings and allegations against Eli Lilly without overt ideological slant. It reports on the court's decision and the state's claims against the pharmaceutical company, but does not take a clear stance on the broader issue of drug pricing or the role of government.
